Drugs / GP40321
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07070752 | Apr → Nov 2023 | type 1 diabetes mellitus | Geropharm | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP40321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07070752 ↗ |
| Modality | Protein / enzyme biologic | “a biosimilar insulin glulisine candidate (T-Glu)” PMID 41366610 ↗ Dec 2025 |
| Route | Subcutaneous | “GP40321, solution for subcutaneous injection, 100 U/mL (GEROPHARM LLC, Russia)” NCT07070752 ↗ |